A second-generation melanoma vaccine being developed at UVA Cancer Center improves long-term survival for melanoma patients compared with the first-generation vaccine, new research shows.
Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.